Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). - Rapoport, Bernardo; Chua, Daniel; Poma, Allen; Arora, Sujata; Wang, Yan; Fein, Luis; Fein, Luis Enrique (Supportive Care in Cancer, 2015)